Medical Affairs Werkstudent
About the job
- The candidate must be an enrolled student of Medicine, Pharmacy, Biology, Biochemistry, Health Sciences, or a comparable natural-science degree program.
- The candidate must have an interest in medical-scientific topics.
- The candidate must work in a structured, independent, and reliable manner.
- The candidate must have strong organizational skills and a high degree of accuracy.
- The candidate must be proficient in Microsoft Office, including PowerPoint, Excel, and Word.
- The candidate must have very good written and spoken German and English skills.
- Provide administrative support to the Medical Affairs team.
- Assist with organizing medical events and congresses.
- Research and prepare medical-scientific literature and publications.
- Assist with presentations and summaries.
- Collaborate with internal departments such as Marketing, Market Access, and Sales.
- Initial experience in scientific work or project management is advantageous.
About the company
Ascendis Pharma develops medicines using its TransCon technology to create long-acting prodrugs for rare endocrine diseases, with broader work in oncology and ophthalmology. The TransCon platform temporarily links an active drug to an inert carrier, releasing the drug in a predictable, sustained way after injection to improve efficacy and reduce dosing frequency. It differentiates itself through its proprietary delivery approach and strategic collaborations, including a worldwide license agreement with Novo Nordisk for GLP-1 TransCon work. The company aims to improve patient outcomes with less frequent, more predictable dosing while expanding its pipeline across endocrine diseases, cancer, and eye disorders.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Gentofte Municipality, Denmark
Founded
2007
Get referred to Ascendis Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 product revenue hit €315 million, up 105% year over year.
- YUVIWEL launched in 2026, with over 220 U.S. patients enrolled by July.
- September 2026 BioMarin settlement cleared litigation and restored full TransCon rights in obesity.
What critics are saying
- YORVIPATH drove €252 million of Q2 2026 revenue; launch concentration remains severe.
- BioMarin royalties through May 2030 tax YUVIWEL sales and weaken achondroplasia economics.
- Any YORVIPATH reimbursement slowdown would crush cash generation and re-rate Ascendis sharply.
What makes Ascendis Pharma unique
- TransCon repeatedly turns peptides into weekly or monthly drugs, not daily injections.
- Ascendis has three approved TransCon products: SKYTROFA, YORVIPATH, and YUVIWEL.
- Management now monetizes the platform across rare endocrine disease and obesity programs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Vision Insurance
Dental Insurance
Parental Leave
Commuter Benefits
Disability Insurance
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Ascendis to share latest advances in hypoparathyroidism and achondroplasia programs at ASBMR 2026. COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon(R) PTH (palopegteriparatide) over a 5-year period. "Our growing body of clinical trial data continues to illustrate the unique potential for our differentiated TransCon-based therapies to improve patient health and quality of life," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Phar... Third-Party Content Disclaimer Content displayed on this platform may include news articles, reports, and other materials aggregated from publicly available third-party sources through automated tools. Such content is not created, written, commissioned, or edited by Straits Interactive Pte Ltd or the Data Protection Excellence (DPEX) Network. While DPEX Network take reasonable steps to ensure responsible publication, DPEX Network do not independently verify all third-party information and make no representations as to its accuracy, completeness, or reliability. The views, findings, and statements expressed in third-party content belong solely to the original source and do not reflect the views of Straits Interactive Pte Ltd or the DPEX Network. If you believe any content is inaccurate, infringing, or should be removed, please contact DPEX Network at [email protected]. DPEX Network will review the matter and, where appropriate, take action in accordance with its internal policies.
Top growth stocks to follow today - september 19th. Prologis, Ascendis Pharma A/S, Teledyne Technologies, Jersey Mike's, and Pershing Square are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to increase their revenue, earnings, or market value faster than the broader market. Investors typically accept higher valuations and greater risk for the potential of substantial long-term returns, and these companies often reinvest profits into expansion rather than paying large dividends. These companies had the highest dollar trading volume of any Growth stocks within the last several days. Prologis (PLD). Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries. Discover more Explore AI Tools Track Stocks Bonds Ascendis Pharma A/S (ASND). Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Teledyne Technologies (TDY). Teledyne Technologies Incorporated, together with its subsidiaries, provides enabling technologies for industrial growth markets in the United States and internationally. Its Digital Imaging segment provides visible spectrum sensors and digital cameras; and infrared, ultraviolet, visible, and X-ray spectra; as well as micro electromechanical systems and semiconductors, including analog-to-digital and digital-to-analog converters. Jersey Mike's (JMKE). Daily Political is Jersey Mike's: A high-growth franchisor of fast casual, submarine-style sandwich restaurants specializing in authentic, hand-crafted, craveable subs. Built over 70 years on one uncompromising belief - that a truly great sub sandwich can change your day and that a truly great brand changes its community - Jersey Mike's is now one of the largest and fastest-growing limited-service restaurant brands based on U.S. Pershing Square (PS). Daily Political is an alternative asset management company that manages pools of permanent capital invested in long-term, high-return investment strategies. Its growth is principally driven by the long-term compounding of its assets under management and the opportunistic launch of new permanent capital vehicles that enable Daily Political to pursue new investment verticals or to pursue its core investment strategies in new jurisdictions.
Ascendis Pharma has authorised a share buyback programme of up to $400 million. The Danish biotech reported product revenue of €315 million for the quarter ending 30 June, up 105% year-on-year, driven largely by its YORVIPATH treatment, which generated €252 million. The company swung to an operating profit of €220 million from a year-earlier loss, supported by a €158 million sale of a priority review voucher. Cash operations generated €274 million in the first half of 2026. However, the buyback remains discretionary. Ascendis can modify, suspend, or cancel the programme at any time. YORVIPATH accounts for most revenue, while selling and administrative costs rose to €173 million from €108 million year-on-year as the company expands commercially.
Ascendis to regain rights to TransCon technology in metabolic and cardiovascular diseases. Globe Newswire 14-Sep-2026 6:00 PM - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (NASDAQ:ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024. Under the terms of the agreement, following termination all licenses granted to Novo Nordisk in metabolic and cardiovascular diseases, including for once-monthly TransCon Semaglutide, will revert to Ascendis, and neither party has any continuing financial obligations to the other. Upon effective termination and reversion of rights, Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications, where it believes it can establish best-in-class therapies. These new programs include advancing once-monthly TransCon Semaglutide, an investigational long-acting prodrug of the GLP-1 receptor agonist semaglutide, as a potential treatment for obesity and type 2 diabetes. "Our mission is to always make a meaningful difference for patients and Ascendis now plans to initiate multiple new programs in cardiovascular and metabolic diseases, including obesity, focusing where the unmet medical needs are greatest," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "Our algorithm for product innovation has delivered three consecutive approved products and we are excited to apply our versatile TransCon platform with the same disciplined approach across these therapeutic areas, consistent with Vision 2030."
BioMarin (BMRN) secured 20% U.S. Royalties on Yuviwel. Is monetizing a rival better than blocking it? Published September 4, 2026 at 12:26 pm EDT BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. will receive royalties equal to 20% of U.S. Yuviwel net sales, retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea through May 2030. The settlement resolves proceedings before the U.S. International Trade Commission and courts in several countries. The financial question is whether those royalties can offset the competitive pressure on Voxzogo. Bull case. The agreement eliminates litigation costs and uncertainty over excluding Yuviwel from major markets. BioMarin Pharmaceutical Inc. instead gains royalties without funding Yuviwel's manufacturing, commercialization, or clinical development. That income should carry lower incremental costs than product sales. Yuviwel remains early in its launch. Ascendis Pharma A/S reported €8 million of second-quarter 2026 Yuviwel revenue and more than 220 unique U.S. patient enrollments through July 31, with over 65% approved for reimbursement. Payments to BioMarin Pharmaceutical Inc. remain limited but will rise if Yuviwel net sales increase. The license extends beyond Yuviwel's current achondroplasia indication. It covers patents held by BioMarin Pharmaceutical Inc. relating to all current and potential Yuviwel indications, including hypochondroplasia, and Yuviwel combinations with other medicines. BioMarin Pharmaceutical Inc. will participate in some economic upside if Ascendis Pharma A/S expands the franchise. The retroactive U.S. provision is another benefit. BioMarin Pharmaceutical Inc. will receive royalties from Yuviwel's first commercial sale rather than only from the settlement date. Bear case. Royalties do not eliminate cannibalization. BioMarin Pharmaceutical Inc. expects Voxzogo revenue of $1.0 billion to $1.05 billion in 2026, making the daily injection a major franchise. Yuviwel's once-weekly dosing could attract patients who otherwise would have used Voxzogo. If one dollar of Yuviwel sales directly replaces one dollar of Voxzogo sales, a 20% royalty recovers only part of the displaced revenue. The economic effect will depend on product margins, pricing, market expansion, and how likely BioMarin Pharmaceutical Inc. was to prevail in the litigation. The settlement is more attractive if Yuviwel brings additional patients into treatment rather than primarily taking market share. The broad license also reduces future blocking leverage. Hypochondroplasia and combination therapy could become important extensions, yet patents held by BioMarin Pharmaceutical Inc. relating to those potential Yuviwel uses are now licensed through the settlement. The royalties apply for a relatively short period ending in May 2030 and cover only specified international markets outside the United States. Yuviwel also received accelerated U.S. approval based on improved annualized growth velocity. Continued approval may depend on confirmatory evidence of clinical benefit. Weak adoption would limit royalty income, while strong adoption could intensify competition with Voxzogo. Hedge fund sentiment. The filings available so far reflect positions held before BioMarin Pharmaceutical Inc. announced the global Yuviwel patent settlement. Insider Monkey's database showed 54 hedge funds holding BioMarin Pharmaceutical Inc. at the end of 2Q2026, down from 62 funds three months earlier. Conclusion. Monetization is financially rational because it removes legal costs and captures part of Yuviwel's future economics. However, the royalty is a partial hedge rather than a complete answer to competition. The agreement creates clear value if Yuviwel expands the treated population or succeeds in additional indications. If Yuviwel mainly displaces Voxzogo, BioMarin Pharmaceutical Inc. will receive royalties while surrendering potentially higher-value product economics. The outcome therefore depends on whether market expansion outweighs franchise cannibalization through May 2030.